FibroScan行肝脏硬度检测和APRI评估慢性丙型肝炎患者肝纤维化程度价值比较*

doi:10.3969/j.issn.1672-5069.2021.04.010

摘要/Abstract

摘要： 目的探讨使用FibroScan行肝脏硬度检测(LSM)和应用门冬氨酸氨基转移酶/血小板比值(APRI)评估慢性丙型肝炎(CHC)患者肝纤维化程度的价值。方法 2016年5月～2020年5月我院收治的CHC患者133例和同期健康体检者133名,接受FibroScan检查及血生化和血液检查,计算APRI。CHC患者接受肝穿刺活检。结果 CHC患者LSM和APRI分别为(10.3±4.2)和(0.8±0.3),显著高于健康人【分别为(4.3±2.0)和(0.3±0.1),P＜0.05】;52例S₁期患者LSM和APRI分别为(6.5±2.4)和(0.6±0.2),37例S₂期患者LSM和APRI分别为(10.3±2.9)和(0.9±0.3),28例S₃期患者LSM和APRI分别为(14.5±4.1)和(1.2±0.5),16例S₄期患者LSM和APRI分别为(18.4±5.7)和(1.8±0.6),相差显著(P＜0.05);经ROC分析LSM预测CHC患者显著肝纤维化(大于等于S2)的曲线下面积(AUC)为0.891,标准误为0.033,P=0.000,95%可信区间为0.826～0.956,最佳截断点为11.200,其诊断的敏感度为0.625,特异度为0.925,而APRI预测CHC患者显著肝纤维化的AUC为0.776,标准误为0.050,P=0.000,95%可信区间为0.678～0.875,最佳截断点为0.795,其敏感度为0.643,特异度为0.887;经相关性分析发现,LSM和APRI与CHC患者肝纤维化程度呈正相关(P＜0.05)。结论应用LSM和APRI评估CHC患者肝纤维化程度有一定的临床价值,特别是对于存在显著肝纤维化的患者,可早期作出病情判断,对指导临床处理有很大的帮助,值得进一步研究。

关键词: 慢性丙型肝炎, 肝纤维化, 肝脏硬度检测, 门冬氨酸氨基转移酶/血小板比值, 诊断

Abstract: Objective The aim of this study was to predict liver fibrosis by liver stiffness measurement (LSM) and aspartate aminotransferase/platelet ratio (APRI) in patients with chronic hepatitis C (CHC). Methods A total of 133 patients with CHC and 133 volunteers were enrolled in this study in our hospital between May 2016 and May 2020, and all of them underwent LSM by FibroScan check-up and got APRI in clinic assessment. All CHC patients received liver biopsies for liver fibrosis evaluation. Results The LSM and APRI in patients with CHC were (10.3±4.2) and (0.8±0.3), both significantly higher than [(4.3±2.0) and (0.3±0.1), respectively, P＜0.05] in healthy persons; the LSM and APRI in 52 patients with liver fibrosis stage 1 (S₁) were (6.5±2.4) and (0.6±0.2), in 37 with S₂ were (10.3±2.9) and (0.9±0.3), in 28 with S₃ were (14.5±4.1) and (1.2±0.5), in 16 with S₄ were (18.4±5.7) and (1.8±0.6), significantly different among them (P＜0.05); the ROC analysis showed that the AUC of LSM was 0.891 in predicting significant liver fibrosis defined as equal to or greater than S2, with the standard error (SE) of 0.033 (P=0.000, 95% confidence interval (CI) of 0.826-0.956), the primal cut-off-value of 11.200, the sensitivity (Se) of 0.625 and the specificity (Sp) of 0.925, while the AUC of APRI was 0.776, with the SE of 0.050 (P=0.000, 95% CI of 0.678-0.875, the cut-off-value of 0.795, the Se of 0.643 and Sp of 0.887; both the LSM and APRI were positively correlated to liver fibrosis in patients with CHC(P＜0.05). Conclusion Both LSM and APRI could be applied to the diagnosis and staging assessment of liver fibrosis in patients with CHC, which warrants further multi-central clinical investigation.

Key words: Hepatitis C, Liver fibrosis, Liver stiffness measurement, Aspartate aminotransferase/platelet ratio, Diagnosis

安红杰, 徐金凤, 耿华, 葛志胜, 何文艳, 赵崇山, 高美丽, 陈俊, 周东方. FibroScan行肝脏硬度检测和APRI评估慢性丙型肝炎患者肝纤维化程度价值比较^*[J]. 实用肝脏病杂志, 2021, 24(4): 492-495.

An Hongjie, Xu Jinfeng, Geng Hua, et al. Prediction of liver fibrosis by liver stiffness measurement andaspartate aminotransferase/platelet ratio in patients with chronic hepatitis C[J]. Journal of Practical Hepatology, 2021, 24(4): 492-495.

参考文献

[1] Peter Ferenci. Viral hepatitis: cure of chronic hepatitis C-required length of follow-up? Nat Rev Gastroenterol Hepatol, 2015, 12(1):10-11.
[2] Kantari-Mimoun C, Castells M, Klose R, et al. Resolution of liver fibrosis requires myeloid cell-driven sinusoidal angiogenesis. Hepatology, 2015, 61(6):2042-2055.
[3] Barr RG, Ferraioli G, Palmeri ML, et al. Elastography assessment of liver fibrosis: society of radiologists in ultrasound consensus conference statement. Radiology, 2015, 276(3):845-861.
[4] Saikia A, Bose M, Barman NN, et al. Molecular epidemiology of HBV infection in chronic hepatitis B virus infected patients in northeast India. J Med Virol, 2015, 87(9):1539-1548.
[5] Kew MC. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol, 2010, 58(4):273-277.
[6] Cadranel JF, Lahmek P, Causse X, et al. Epidemiology of chronic hepatitis B infection in France: risk factors for significant fibrosis - results of a nationwide survey. Aliment Pharmacol Ther, 2007, 26(4):565-576.
[7] 中华医学会肝病学分会, 中华医学会感染病学分会. 《丙型肝炎防治指南》2015年更新版. 实用肝脏病杂志, 2016, 19(4):521-538.
[8] 曾民德, 王泰龄. 肝纤维化诊断及疗效评估共识. 中华肝脏病杂志, 2002, 10(5):327-328.
[9] Suh B, Park S, Shin DW, et al. High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. Hepatology, 2015, 61(4):1261-1268.
[10] Lee HW, Kang W, Kim BK, et al. Red cell volume distribution width-to-platelet ratio in assessment of liver fibrosis in patients with chronic hepatitis B. Liver Int, 2016, 36(1):24-30.
[11] Myers RP, Crotty P, Pomier-Layrargues G, et al. Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy. liver Int, 2010, 30(10):1471-1480.
[12] Castera L, Bedossa P. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy? liver Int, 2011, 31(1):13-17.
[13] Chirag S, Fomda BA, Khan A, et al. Detection of hydatid-specific antibodies in the serum and urine for the diagnosis of cystic echinococcosis in patients from the Kashmir Valley, India. J Helminthol, 2015, 89(2):232-237.
[14] Fernando SM, Tran A, Cheng W, et al. Necrotizing soft tissue infection: diagnostic accuracy of physical examination, imaging, and lrinec score: a systematic review and meta-analysis. Ann Surg, 2019, 269(1):58-65.
[15] Jin YS, Wang K, Tian J. Preoperative examination and intraoperative identification of hepatocellular carcinoma using a targeted bimodal imaging prob. Bioconjug Chem, 2018, 29(4):1475-1784.
[16] Seo YS, Kim MY, Kim SU, et al. Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: a multicentre, retrospective study. Liver Int, 2015, 35(10):2246-2255.
[17] 袁利超, 邵金华, 郝美娜, 等. 肝脏硬度测定仪FibroTouch与FibroScan和肝脏病理分期的相关性. 中华肝脏病杂志, 2014, 22(6):425-429.
[18] Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol, 2015, 64(4):773-780.
[19] 张孝盈, 钱静, 李萍, 等. 无创方法诊断慢性乙型肝炎病毒携带者肝纤维化的临床价值. 中华肝脏病杂志, 2018, 26(5):332-336.
[20] 欧晓娟, 王晓明, 吴晓宁, 等. FibroTouch与FibroScan在慢性乙型肝炎患者肝纤维化评估中的比较. 中华肝脏病杂志, 2015, 23(2):103-106.

FibroScan行肝脏硬度检测和APRI评估慢性丙型肝炎患者肝纤维化程度价值比较^*

Prediction of liver fibrosis by liver stiffness measurement andaspartate aminotransferase/platelet ratio in patients with chronic hepatitis C

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨艳秋, 程颢, 冯敏. 肝脏剪切波弹性成像对慢性乙型肝炎患者肝纤维化的评估价值^*[J]. 实用肝脏病杂志, 2021, 24(4): 480-483.
[2]	孙海荣, 冯伟广, 周冰清, 刘慧敏, 蒋蓓莉. 不同血清ALT水平的乙型肝炎病毒感染者肝纤维化指标变化[J]. 实用肝脏病杂志, 2021, 24(4): 488-491.
[3]	王嘉妮, 刘湧, 周忻, 任传路, 缪惠锴. 慢性丙型肝炎患者血清microRNA-1273g-3p水平预测肝硬化价值分析^*[J]. 实用肝脏病杂志, 2021, 24(4): 496-499.
[4]	欧南, 魏梅, 王劲, 彭正伟. 应用MRI多回波水脂分离技术评估非酒精性脂肪性肝病患者肝脏脂肪含量效能研究^*[J]. 实用肝脏病杂志, 2021, 24(4): 508-511.
[5]	殷志勇, 王连双, 张瑶. 超声检查门静脉海绵样变特征表现[J]. 实用肝脏病杂志, 2021, 24(4): 540-543.
[6]	陈永超, 周旺, 李岩, 张超学. 超声造影指导肝穿刺对肝脏占位性病变的诊断价值研究^*[J]. 实用肝脏病杂志, 2021, 24(4): 569-572.
[7]	朱文莉, 李宝新, 张穿洋, 李晓冉, 傅晓明. 肝包虫病与肝囊肿CT表现比较^*[J]. 实用肝脏病杂志, 2021, 24(4): 577-580.
[8]	彭婕, 李弼民, 雷宇鹏. 四氯化碳诱导的肝纤维化小鼠肝组织和HSC-T6细胞NOX4基因及其蛋白表达的变化[J]. 实用肝脏病杂志, 2021, 24(3): 319-322.
[9]	郝肖伟, 白娜, 郭小军, 陈永刚. 慢性丙型肝炎合并非酒精性脂肪性肝病患者血清A-FABP水平变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(3): 347-350.
[10]	贾群玲, 徐志宾, 韩舒. 非酒精性脂肪性肝病患者磁共振质子密度脂肪分数变化[J]. 实用肝脏病杂志, 2021, 24(3): 359-362.
[11]	刘彦荣, 王苗, 曾果, 许晓亮. MRI弥散加权成像对原发性硬化性胆管炎患者肝纤维化评估价值分析[J]. 实用肝脏病杂志, 2021, 24(3): 375-378.
[12]	南东, 洪金玲, 姜海宇. 应用DCE-MRI技术评估乙型肝炎肝硬化患者食管胃底静脉曲张严重程度的效能分析[J]. 实用肝脏病杂志, 2021, 24(3): 407-410.
[13]	王耀政, 王瑜琳, 林毅. F-FDG PET/CT诊断胆管细胞癌分期价值研究[J]. 实用肝脏病杂志, 2021, 24(3): 427-430.
[14]	干艳英, 钟凯, 官燕玲, 李慧敏. 三种影像学方法诊断肝外胆管结石比较研究[J]. 实用肝脏病杂志, 2021, 24(3): 439-442.
[15]	韩文有, 李向军, 赵森峰, 徐俊梅, 刘博. 术前胆汁CT值测定诊断胆囊泥沙样结石的应用价值分析[J]. 实用肝脏病杂志, 2021, 24(3): 443-446.